References
- Lin CY, Lubin B, Smith S. Inhibition of platelet aggregation by acyl-CoA thioesters. Biochim Biophys Acta 1976; 428: 45–55
- Lascu I, Edwards B, Cucuianu MP, Deamer DW. Platelet aggregation is inhibited by long chain acyl-CoA. Biochem Biophys Res Comm 1988; 156: 1020–1025
- Coddou C, Loyola G, Boyer JL, Bronfman M, Huidobro-Toro JP. The hypolipidemic drug metabolites nafenopin-CoA and ciprofibroyl-CoA are competitive P2Y1 receptor antagonists. FEBS Lett 2003; 536: 145–150
- Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2-deoxyadenosine-3,5-bisphosphate. Br J Pharmacol 1998; 124: 1–3
- Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 2005; 31: 195–204
- Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407–413
- Fox SC, Sasae R, Janson S, May JA, Heptinstall S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets 2004; 15: 85–93
- Merritt JE, McCarthy SA, Davies MPA, Moors KE. Use of fluo-3 to measure cytosolic Ca2+ in platelet and neutrophils. Biochem J 1990; 269: 513–519
- Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P-2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925–934
- Behan MWH, Fox SC, Heptinstall S, Storey RF. Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes. Platelets 2005; 16: 73–80
- Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett. 1998; 422: 291–295
- Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. J Thromb Haemost 2001; 85: 303–308
- Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007–2011
- Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202–207
- Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005; 51: 957–965
- Major DT, Halbfinger E, Fischer B. Molecular recognition of modified adenine nucleotides by the P2Y(1)-receptor. 2. A computational approach. J Med Chem 1999; 42: 5338–5347
- Leonardi R, Zhang Y-M, Rock CO, Jackowski S, Coenzyme A. Back in action. Prog Lipid Res 2005; 44: 125–153
- Glatz JF, Vork MM, van der Vusse GJ. Significance of cytoplasmic fatty acid-binding protein for the ischemic heart. Mol Cell Biochem 1993; 123: 167–173
- Vork MM, Glatz JF, van der Vusse GJ. Release of fatty acid-binding protein and long chain fatty acids from isolated rat heart after ischemia and subsequent calcium paradox. Mol Cell Biochem 1993; 123: 175–184
- Vork MM, Glatz JF, Surtel DA, Van der Vusse GJ. Release of fatty acid binding protein and lactate dehydrogenase from isolated rat heart during normoxia, low-flow ischemia, and reperfusion. Can J Physiol Pharmacol 1993; 71: 952–958